Fortrea vs Labcorp
FTRE and LH side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How FTRE and LH compare
Labcorp is the larger company, worth 15 times as much as Fortrea ($29.9B against $2.0B).
Labcorp grew revenue faster over the last twelve months (6.0% versus −3.4% for Fortrea).
Labcorp keeps more of each dollar of sales as profit, with a net margin of 6.9% compared with −2.6% at Fortrea.
Labcorp pays a dividend yielding 0.78%; Fortrea does not pay one.
Labcorp scores higher on the StockData Score (11 against 4 for Fortrea), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | FTRE | LH |
|---|---|---|
| Size and price | ||
| Market cap | $2.0B | $29.9B |
| Share price | $21.29 | $368.16 |
| Change, 1 year | 104% | 41.8% |
| Change, 5 years | – | 34.0% |
| Beta (5Y) | 1.49 | 0.61 |
| Employees | 14K | 71K |
| StockData Score | ||
| Total score | 4 | 11 (better) |
| Valuation score | 0 | 0 |
| Growth score | 2 | 2 |
| Performance score | 2 | 2 |
| Health score | 0 | 4 (better) |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/E | – | 30.2× |
| P/S | 0.8× (better) | 2.0× |
| P/B | 3.8× | 3.4× (better) |
| EV/EBITDA | 31.3× | 16.0× (better) |
| P/FCF | 12.0× (better) | 23.2× |
| FCF yield | 8.3% (better) | 4.3% |
| Fair value | $17.16 | $356.26 |
| Margin of safety | −24.1% | −3.3% (better) |
| Growth | ||
| Revenue growth (TTM) | −3.4% | 6.0% (better) |
| Revenue growth, 5Y average | – | −0.04% |
| Net income growth (TTM) | – | 17.4% |
| EPS growth (TTM) | – | 19.6% |
| EPS growth, 5Y average | – | −8.0% |
| Profitability | ||
| Gross margin | 20.0% | 29.0% (better) |
| Operating margin | 0.48% | 10.3% (better) |
| Net margin | −2.6% | 6.9% (better) |
| FCF margin | 6.3% | 8.8% (better) |
| Return on equity | −12.3% | 11.4% (better) |
| Return on invested capital | 0.69% | 8.6% (better) |
| Financial health | ||
| Debt / equity | 1.98 | 0.66 (better) |
| Net debt / EBITDA | 9.12 | 2.53 (better) |
| Interest coverage | – | 6.5× |
| Current ratio | 0.97 | 1.41 (better) |
| Altman Z-score | 0.80 | 3.55 (better) |
| Piotroski F-score | 3 | 7 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 0.78% |
| Payout ratio | – | 23.6% |
| Years of dividend growth | – | 0 |
| Buyback yield | – | 2.3% |
| Shareholder yield | 0.00% | 3.0% (better) |
| Ownership | ||
| Held by institutions | 105% | 98.0% |
| Held by insiders | 4.0% | 0.40% |
| Insider net buying, 12 months | −$4.7M (better) | −$11.9M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 13.8% | 3.3% |
Go deeper
- FTRE stock overview
- FTRE income statement
- FTRE valuation and score
- LH stock overview
- LH income statement
- LH valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.